Acrivon Therapeutics Inc (NASDAQ: ACRV) on Monday, soared 6.25% from the previous trading day, before settling in for the closing price of $2.24. Within the past 52 weeks, ACRV’s price has moved between $1.05 and $8.35.
Annual sales at Healthcare sector company slipped by -74.96% over the past five years. The company achieved an average annual earnings per share of 15.22%. With a float of $22.47 million, this company’s outstanding shares have now reached $31.55 million.
Acrivon Therapeutics Inc (ACRV) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Acrivon Therapeutics Inc is 28.78%, while institutional ownership is 48.72%. The most recent insider transaction that took place on Apr 30 ’25, was worth 617,412. In this transaction 10% Owner of this company sold 437,881 shares at a rate of $1.41, taking the stock ownership to the 3,403,025 shares. Before that another transaction happened on May 01 ’25, when Company’s 10% Owner sold 298,886 for $1.34, making the entire transaction worth $400,507. This insider now owns 3,104,139 shares in total.
Acrivon Therapeutics Inc (ACRV) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.54 earnings per share (EPS) for the period topping the consensus outlook (set at -0.7) by 0.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.55 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.12% during the next five years compared to -74.96% drop over the previous five years of trading.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Trading Performance Indicators
Acrivon Therapeutics Inc (ACRV) is currently performing well based on its current performance indicators. A quick ratio of 8.75 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.13, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.85 in one year’s time.
Technical Analysis of Acrivon Therapeutics Inc (ACRV)
Acrivon Therapeutics Inc (NASDAQ: ACRV) saw its 5-day average volume 1.02 million, a positive change from its year-to-date volume of 0.78 million. As of the previous 9 days, the stock’s Stochastic %D was 69.92%.
During the past 100 days, Acrivon Therapeutics Inc’s (ACRV) raw stochastic average was set at 80.92%, which indicates a significant decrease from 85.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.20 in the past 14 days, which was higher than the 0.13 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.87, while its 200-day Moving Average is $2.25. Nevertheless, the first resistance level for the watch stands at $2.51 in the near term. At $2.64, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.80. If the price goes on to break the first support level at $2.22, it is likely to go to the next support level at $2.06. Assuming the price breaks the second support level, the third support level stands at $1.93.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Key Stats
Market capitalization of the company is 75.10 million based on 31,456K outstanding shares. Right now, sales total 0 K and income totals -80,560 K. The company made 0 K in profit during its latest quarter, and -21,010 K in sales during its previous quarter.
